New lung cancer drug HB0025 faces off against standard therapy in major trial
NCT ID NCT07383116
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial will test whether a new drug called HB0025, combined with standard chemotherapy, works better than the current treatment tislelizumab plus chemotherapy for people with advanced nonsquamous non-small cell lung cancer. About 500 participants will be randomly assigned to one of the two treatment groups. The main goal is to see how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HB0025 injection (a new drug) combined with chemotherapy (pemetrexed plus carboplatin or cisplatin)
- What this could lead to
- If successful, this could offer a new first-line treatment option for people with advanced nonsquamous non-small cell lung cancer, potentially improving how long the cancer is kept under control.
- What could go wrong
- This is an early-stage Phase 3 trial that hasn't started recruiting yet. The new drug HB0025 may not be more effective than the existing treatment tislelizumab, and side effects from the combination are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SQUAMOUS NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The East Hospital Affiliated to Tongji University
Shanghai, Shanghai 200120, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a novel drug combo outperform standard chemo for lung cancer?
- Can a Four-Drug cocktail shrink Hard-to-Treat lung tumors?
- New lung cancer drug aims to match Keytruda's success
- Targeted drug shows promise for Gene-Driven lung cancers
- Engineered virus plus immunotherapy aims to outperform chemo in advanced lung cancer
- New drug duo aims to tackle Hard-to-Treat cancers